MX2017004359A - Composiciones farmaceuticas que comprenden alpelisib. - Google Patents
Composiciones farmaceuticas que comprenden alpelisib.Info
- Publication number
- MX2017004359A MX2017004359A MX2017004359A MX2017004359A MX2017004359A MX 2017004359 A MX2017004359 A MX 2017004359A MX 2017004359 A MX2017004359 A MX 2017004359A MX 2017004359 A MX2017004359 A MX 2017004359A MX 2017004359 A MX2017004359 A MX 2017004359A
- Authority
- MX
- Mexico
- Prior art keywords
- alpelisib
- pharmaceutical compositions
- amide
- thiazol
- trifluoro
- Prior art date
Links
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 title 1
- 229950010482 alpelisib Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- OAWXZFGKDDFTGS-BYPYZUCNSA-N (2s)-pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(O)=O OAWXZFGKDDFTGS-BYPYZUCNSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000007919 dispersible tablet Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Dispersion Chemistry (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462059331P | 2014-10-03 | 2014-10-03 | |
| PCT/IB2015/057523 WO2016051374A1 (en) | 2014-10-03 | 2015-10-01 | Pharmaceutical compositions comprising alpelisib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017004359A true MX2017004359A (es) | 2017-06-23 |
Family
ID=54292871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017004359A MX2017004359A (es) | 2014-10-03 | 2015-10-01 | Composiciones farmaceuticas que comprenden alpelisib. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20170296523A1 (enExample) |
| EP (2) | EP3200772B1 (enExample) |
| JP (1) | JP6723229B2 (enExample) |
| KR (2) | KR102598782B1 (enExample) |
| CN (2) | CN112957334B (enExample) |
| AU (1) | AU2015326392B2 (enExample) |
| BR (1) | BR112017004694A2 (enExample) |
| CA (1) | CA2962714C (enExample) |
| ES (1) | ES2929554T3 (enExample) |
| MX (1) | MX2017004359A (enExample) |
| PL (1) | PL3200772T3 (enExample) |
| PT (1) | PT3200772T (enExample) |
| RU (1) | RU2690685C2 (enExample) |
| WO (1) | WO2016051374A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105919957A (zh) * | 2016-06-13 | 2016-09-07 | 佛山市腾瑞医药科技有限公司 | 一种艾代拉利司分散片及其制备方法 |
| AR116299A1 (es) | 2018-09-07 | 2021-04-21 | Sanofi Sa | Sales de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilato de metilo y proceso de preparación de las mismas |
| TW202146007A (zh) | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| US20240156752A1 (en) * | 2021-03-11 | 2024-05-16 | Atossa Therapeutics, Inc. | Endoxifen for treatment of ovarian cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698226A (en) * | 1993-07-13 | 1997-12-16 | Glaxo Wellcome Inc. | Water-dispersible tablets |
| ES2082723B1 (es) * | 1994-07-20 | 1996-10-01 | Lilly Sa | Formulacion farmaceutica de fluoxetina en forma dispersable. |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| WO2011080502A2 (en) * | 2009-12-29 | 2011-07-07 | Orexo Ab | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
| AR082418A1 (es) * | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
| PH12013502077A1 (en) * | 2011-04-25 | 2013-12-16 | Novartis Ag | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor |
| WO2012170488A1 (en) * | 2011-06-07 | 2012-12-13 | Zx Pharma, Llc | Multiparticulate s-adenosylmethionine compositions and related methods |
| CA2839621A1 (en) * | 2011-06-21 | 2012-12-27 | Novartis Ag | Polymorphs of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide |
| BR112014023530A2 (pt) * | 2012-03-29 | 2017-07-18 | Novartis Ag | diagnóstico farmacêutico |
| US9827200B2 (en) * | 2012-04-24 | 2017-11-28 | Daiichi Sankyo Company, Limited | Orally disintegrating tablet and production process therefor |
| WO2014007780A1 (en) * | 2012-07-06 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Orally-disintegrating formulations of dexketoprofen |
| EP2742940B1 (en) * | 2012-12-13 | 2017-07-26 | IP Gesellschaft für Management mbH | Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily |
-
2015
- 2015-10-01 CN CN202110187770.1A patent/CN112957334B/zh active Active
- 2015-10-01 AU AU2015326392A patent/AU2015326392B2/en active Active
- 2015-10-01 BR BR112017004694A patent/BR112017004694A2/pt not_active Application Discontinuation
- 2015-10-01 ES ES15778761T patent/ES2929554T3/es active Active
- 2015-10-01 RU RU2017114195A patent/RU2690685C2/ru active
- 2015-10-01 PL PL15778761.5T patent/PL3200772T3/pl unknown
- 2015-10-01 MX MX2017004359A patent/MX2017004359A/es unknown
- 2015-10-01 KR KR1020237000178A patent/KR102598782B1/ko active Active
- 2015-10-01 EP EP15778761.5A patent/EP3200772B1/en active Active
- 2015-10-01 WO PCT/IB2015/057523 patent/WO2016051374A1/en not_active Ceased
- 2015-10-01 US US15/515,621 patent/US20170296523A1/en not_active Abandoned
- 2015-10-01 PT PT157787615T patent/PT3200772T/pt unknown
- 2015-10-01 JP JP2017517262A patent/JP6723229B2/ja active Active
- 2015-10-01 CN CN201580054000.2A patent/CN107106497A/zh active Pending
- 2015-10-01 CA CA2962714A patent/CA2962714C/en active Active
- 2015-10-01 EP EP22187029.8A patent/EP4169508A1/en active Pending
- 2015-10-01 KR KR1020177008575A patent/KR102486126B1/ko active Active
-
2019
- 2019-04-15 US US16/363,004 patent/US20190314353A1/en not_active Abandoned
-
2022
- 2022-06-29 US US17/853,537 patent/US20220331305A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015326392B2 (en) | 2018-10-04 |
| KR20230008913A (ko) | 2023-01-16 |
| US20220331305A1 (en) | 2022-10-20 |
| KR102486126B1 (ko) | 2023-01-09 |
| RU2017114195A (ru) | 2018-11-08 |
| EP3200772B1 (en) | 2022-08-03 |
| EP4169508A1 (en) | 2023-04-26 |
| KR20170056574A (ko) | 2017-05-23 |
| KR102598782B1 (ko) | 2023-11-07 |
| CN112957334B (zh) | 2023-08-04 |
| JP6723229B2 (ja) | 2020-07-15 |
| CN107106497A (zh) | 2017-08-29 |
| EP3200772A1 (en) | 2017-08-09 |
| US20170296523A1 (en) | 2017-10-19 |
| JP2017530143A (ja) | 2017-10-12 |
| RU2017114195A3 (enExample) | 2018-11-16 |
| BR112017004694A2 (pt) | 2017-12-05 |
| CN112957334A (zh) | 2021-06-15 |
| ES2929554T3 (es) | 2022-11-30 |
| PT3200772T (pt) | 2022-10-19 |
| RU2690685C2 (ru) | 2019-06-05 |
| WO2016051374A1 (en) | 2016-04-07 |
| CA2962714C (en) | 2023-09-19 |
| CA2962714A1 (en) | 2016-04-07 |
| AU2015326392A1 (en) | 2017-03-09 |
| US20190314353A1 (en) | 2019-10-17 |
| PL3200772T3 (pl) | 2022-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ721298A (en) | Pharmaceutical compositions comprising azd9291 | |
| JOP20200122A1 (ar) | مركبات مفيدة لتثبيط cdk7 | |
| WO2017100726A8 (en) | Methods for treating huntington's disease | |
| EP3675859A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISEASE | |
| DK3328843T3 (da) | 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning | |
| UY36275A (es) | Compuestos aminopirimidinilo | |
| MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
| HK1255162A1 (zh) | 爱帕琳肽受体激动剂及使用方法 | |
| EA201201263A1 (ru) | Фармацевтическая композиция, содержащая этексилат дабигатрана | |
| WO2016172496A8 (en) | Lsd1 inhibitors and uses thereof | |
| SG11202102440SA (en) | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof | |
| MX2016013431A (es) | Composiciones farmaceuticas que comprenden agentes antibacterianos. | |
| WO2014033526A9 (en) | Pharmaceutical compositions of etoricoxib | |
| HK1257171A1 (zh) | 間變性淋巴瘤激酶（alk）和絲氨酸富集蛋白激酶 （sppk）的抑制劑及其使用方法 | |
| PH12017501397A1 (en) | (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor | |
| EP3184113A4 (en) | Pharmaceutical composition, comprising gold compound, for preventing or treating liver fibrosis or liver cirrhosis | |
| EP3275450A4 (en) | Pharmaceutical composition for preventing or treating inflammatory diseases, containinglactococcus chungangensis | |
| MX2017004359A (es) | Composiciones farmaceuticas que comprenden alpelisib. | |
| WO2015001541A3 (en) | Pharmaceutical film composition | |
| MX2015014958A (es) | Nuevos derivados de triazolona o sales de la misma y composicion farmaceutica que comprende a la misma. | |
| WO2016142821A3 (en) | Compositions containing a thrombin inhibitor | |
| EP3182986A4 (en) | Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan | |
| EA201691792A1 (ru) | Фармацевтические составы на основе вилдаглиптина | |
| MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| WO2016109361A3 (en) | 3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase |